The analysis included 1,563 oral ASCO presentations, including 1,242 oral abstracts, 277 rapid oral abstracts and 44 plenary presentations. The 1,310 speakers represented 491 institutions.

Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology ...

YANTAI, China, June 2, 2025 /PRNewswire/ -- On June 2 (Chicago time), in an oral presentation at the 2025 ASCO Annual Meeting, Dr. Lin Shen from Beijing Cancer Hospital presented the results of a ...

Dr. Juho Jalkanen, CEO of Faron Pharmaceuticals, said:"We are thrilled to see bexmarilimab's data receive acceptance for oral presentation at EHA, following similar recognition at MDS and ASCO.

Aptose is developing TUS+VEN+AZA as a one-of-a-kind safe and mutation agnostic frontline triple drug therapy for newly diagnosed AML Oral presentation at EHA will include updated data at the 40 mg and ...

Thousand Oaks, Calif.-based Capsida Biotherapeutics (Capsida) has announced its slate of seven scientific presentations, three oral and four in poster form, that have been accepted for the 28th Annual ...

A rapid oral presentation is part of a formal session, with a six-minute oral presentation format. It aims at sharing clinical data that stood out among many submissions. The company will also present ...

Candel Therapeutics announced an oral presentation of CAN-2409 data at the ASCO Annual Meeting, focusing on prostate cancer treatment.

All students in the oral presentation must submit at least one slide to accompany their presentation. All presentation slides must be submitted in PowerPoint (PPT) format. Slides should not include ...

VALBIOTIS SA VALBIOTIS : Oral presentation at the 2024 EASD congress 05-Sep-2024 / 17:40 CET/CEST Dissemination of a French Regulatory News, transmitted by EQS Group. The issuer is solely ...